Doris Macharia Elected President of TB Alliance’s Global TB Stakeholders, Joins Board of Directors
Global health leader brings deep expertise in advancing children’s health, HIV, and global health equity NEW YORK (March 2, 2026)—TB
Press Releases
TB Alliance Announces New Collaboration with Novartis to Advance the Research and Development of Telacebec for Leprosy
New collaboration aims to advance innovation for a neglected and stigmatizing disease affecting hundreds of thousands worldwide NEW YORK (January
TB Alliance and Asian Development Bank Forge Strategic Partnership to Strengthen Regional Efforts Against Tuberculosis
New York, USA and Manila, Philippines — [Date] — TB Alliance and the Asian Development Bank (ADB) have announced a
Promising New Data on Pediatric Use of Pretomanid in Children with Drug-Resistant Tuberculosis Presented at 2025 Union Conference
Positive results mark an important step forward in efforts to develop effective treatments for children with drug-resistant TB COPENHAGEN, Denmark
Phase 2 Clinical Trial Results Show Potential to Shorten TB Treatment Time
Thuto Pulane, a TB survivor and participant in the NC-009 trial, at a follow-up appointment with Dr. William Brumskine, NC-009
Realizing our “Triple-A Mandate”
Four years ago, TB Alliance secured the first regulatory approval from the United States Food and Drug Administration (US FDA)
TB Alliance Issues Call for Researchers to Access TB Biomarker Repository
NEW YORK (March 23, 2021) – Interested researchers are invited to apply to access the MARK-TB (Markedly Accelerating Research with
Results of Phase 2B Clinical Trial Testing New Drug-Resistant TB Treatment Published in Lancet Respiratory Medicine
November 13, 2019 – Results of the Phase 2B trial, known as NC-005 have been published in The Lancet Respiratory Medicine.
TB Alliance Welcomes Global Drug Facility’s Listing of Pretomanid
The Stop TB Partnership’s Global Drug Facility (GDF) has added the anti-TB drug pretomanid to its catalog of TB medicines.
TB Alliance and Macleods Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB
NEW YORK and MUMBAI (October 28, 2019)—Non-profit drug developer TB Alliance has granted Macleods Pharmaceuticals Limited a non-exclusive license to